Apnimed has raised $192 million from an upsized IPO to fund the launch of its sleep apnea pill, Oxnimbi (AD109). The company priced the IPO at $16 per share, selling 12 million shares instead of the originally planned 10 million, which were targeted between $14 and $16. The net proceeds from the IPO will be used to support the commercial launch and regulatory approval process for Oxnimbi, which is under FDA review with a decision expected by February 2027. Apnimed shares began trading on the Nasdaq under the ticker symbol APMD; the stock rose sharply in initial trading, opening at $22 and hovering around $17, representing a strong market reception. Sources: Apnimed's IPO dream comes true with upsized $192M IPO Sleep-Apnea Biotech Apnimed Shares Jump After Upsized US IPO Apnimed Announces Pricing of Upsized Initial Public Offering Sleep-Apnea Biotech Apnimed Shares Jump After Upsized US IPO Cambridge biotech raises $192M in upsized IPO ahead of major FDA ... Slee...
- Get link
- X
- Other Apps